CurrentUnitedHealthcarePolicy CS036PA.W

Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Pennsylvania Only)

Policy governing coverage of electrical stimulation therapies (TENS, FES, NMES, and related modalities) for members in Pennsylvania; defines covered, unproven, and not medically necessary indications and links to coding and documentation expectations.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Pennsylvania Only)

Policy CodePolicy CS036PA.W

Change TypeNo material changes

Effective DateMay 1, 2026

Next Review Date

Key ActionObtain and document prior conservative therapy and clinical justification (including relevant diagnostic tests and functional status) when requesting coverage for implantable or limited‑evidence electrical stimulation therapies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Pennsylvania onlystate scope

FES covered for SCI ambulationFES coverage

NMES covered for select indicationsNMES coverage

≥12 modalitiesUnproven therapies

Multiple HCPCS/CPT codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Electrical Stimulation Therapies

Functional Electrical Stimulation (FES) - Covered Indications

Covered when ALL of the following are met

FES coverage criteria

Neuromuscular and functional prerequisites: Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves); muscle and joint stability for weight-bearing at upper and lower extremities with ability to maintain an upright support posture independently; demonstration of brisk muscle contraction; demonstration of sensory perception sufficient for muscle contraction; demonstration of hand and finger function to manipulate controls; ability to transfer independently; demonstration of independent standing tolerance for at least 3 minutes>= 3 minutes standing tolerance
Patient factors: High level of motivation, commitment, and cognitive ability for device use; post recovery from SCI and restorative surgery of at least 6 months>= 6 months post recovery
Contraindications absent: Absence of hip and knee degenerative disease and absence of history of long bone fracture secondary to osteoporosis

Neuromuscular Electrical Stimulation (NMES) - Covered Indications

Covered when ANY of the following are met

NMES coverage criteria: Neuromuscular electrical stimulation (NMES) is medically necessary for treating disuse muscle atrophy when nerve supply intact and atrophy is non-neurological; OR when used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty; OR to improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program

Transcutaneous Electrical Nerve Stimulation (TENS)

Covered when criteria per InterQual CP are met

TENS coverage: Transcutaneous electrical nerve stimulator (TENS) is proven and medically necessary in certain circumstances when clinical coverage criteria in the InterQual® CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) are met

See InterQual criteria referenced in policy

Unproven / Not Medically Necessary

The following are unproven and not medically necessary due to insufficient evidence of efficacy

Unproven modalities: Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS); Percutaneous electrical nerve stimulation (PENS) / percutaneous neuromodulation therapy (PNT); Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS); Peripheral subcutaneous field stimulation (PSFS) / peripheral nerve field stimulation (PNFS); Pulsed electromagnetic field stimulation (PEMF) / pulsed electrical stimulation (PES); Restorative neurostimulation; Scrambler therapy; Translingual stimulation for gait rehabilitation; and other indications not meeting covered criteria

These modalities are considered unproven/not medically necessary per policy due to insufficient evidence

FES and related neuromodulation evidence summary

Summary of FES evidence and contexts where benefit has been observed

FES benefits in SCI: FES has demonstrated improvements in muscle strength, aerobic capacity, respiratory function, muscle hypertrophy, and some functional outcomes in adults with complete and incomplete spinal cord injury across multiple studies and systematic reviews, particularly when combined with exercise programs

Effect sizes and specific outcomes vary across reviews and cohorts

Limitations and uncertainty: Evidence limitations include small sample sizes, heterogeneous protocols, short follow-up, and mixed long-term functional outcomes; methodological quality is often low-to-fair, indicating need for larger high-quality RCTs

Hayes and other reviews rate quality as low in several populations

Specific positive findings: Meta-analyses and cohort studies report significant improvements in expiratory function and VO2 peak with FES interventions (e.g., FES-assisted rowing/cycling) and gains in motor-sensory scores and muscle mass with long-term FES cycling

See Xiangli et al., Máté et al., and Sadowsky et al. summaries

Evidence summaries by clinical indication

Findings summarized by indication (evidence quality and outcomes):

Spinal Cord Injury: Adults with complete motor SCI: multiple studies/reporting improvements in strength, ambulation, and physiological measures though quality varies; incomplete SCI: some RCT evidence of strength gains but inconsistent functional/QOL outcomes

See systematic reviews and Hayes assessment

Cerebral Palsy: Small RCTs and cohort studies report improvements in ankle dorsiflexion strength, selective motor control, balance, and gait kinematics with FES/NMES in CP; activity and participation outcomes are limited or mixed

Heterogeneous protocols and small samples limit certainty

Stroke (CVA): FES/NMES in stroke shows mixed evidence: some trials report benefits for trunk control, walking distance, and upper-extremity function when added to conventional therapy, while several RCTs show no consistent advantage over AFOs or standard rehab for walking/QOL; overall evidence rated low to moderate with heterogeneity

See Matsumoto, Galvão, Eraifej, and Hayes summaries

Evidence summaries by condition

Summary of clinical findings by condition (evidence quality and observed outcomes):

Stroke-related rehabilitation: Systematic reviews and HTAs report low- to very-low-quality evidence overall; assistive FES may not consistently outperform AFOs for walking/QOL, while FES added to conventional therapy can improve some upper-extremity outcomes; long-term durable benefits are uncertain

Additional high-quality RCTs needed

Multiple Sclerosis: Small studies indicate FES may improve walking speed and perceived exertion comparable to AFOs and may improve QOL in some trials; evidence quality low due to small sizes and device heterogeneity

Chronic Heart Failure and Cardiopulmonary Conditions: Meta-analyses report improvements in peak VO2, 6MWD, and QOL with FES vs control; traditional exercise often yields greater gains; studies are limited by small samples and heterogeneity

Musculoskeletal / Orthopedic (NMES):

Evidence summaries

Evidence statements and study conclusions from the document excerpts:

ACL reconstruction: Systematic review of 11 studies (n=202) found NMES added to rehabilitation significantly increased quadriceps strength in short- and long-term follow-up; functional scores (Lysholm) showed no consistent difference

Earlier NMES (≤1 week) had larger effect per subgroup analyses

Total hip replacement (THR): Small feasibility RCTs report NMES (e.g., geko device) may reduce early postoperative pain during mobilization and calf swelling and increase femoral vein peak velocity, but evidence is limited by small samples and short follow-up

Further larger trials recommended

Poststroke dysphagia: Meta-analysis of 46 RCTs (n=3,346) reported NMES plus swallowing therapy improved swallowing function and QOL and reduced complications; subgroup signals for earlier onset (<20 days) and age >60 showed greater benefit

Heterogeneity and reporting limitations noted

Coverage summary by indication

Summarized conclusions from RCTs and systematic reviews:

Poststroke motor rehabilitation (NMES/CCFES): NMES and CCFES show some improvements in ADLs, swallowing, sEMG response, and manual dexterity in select trials and subgroups, especially when applied in the subacute stage or to the upper extremity; however, results are mixed and additional high-quality trials are needed

Respiratory conditions (COPD) and ICU weakness: NMES combined with pulmonary or standard rehabilitation may improve exercise capacity, quadriceps strength, and QOL in selected studies, but evidence is heterogeneous and of low certainty; NMES should not replace pulmonary rehabilitation

Low back pain and IFT/TENS/EMS: Transcutaneous electrotherapies produce mixed short-term effects; IFT may yield short-term pain/disability reductions in some trials but overall heterogeneity and bias limit confidence in durable benefit

Guideline recommendations: Professional guidelines (NICE, ACP, AAOS) generally state insufficient or limited evidence for routine use of some electrotherapies (IFT, PENS) and recommend conservative nonpharmacologic therapies as first-line

Evidence synthesis for IFT and MENS

Evidence summary relevant to coverage decisions

IFT evidence: IFT shows mixed results: some meta-analyses and RCTs report modest short-term pain and function benefit (knee OA, CLBP), while other trials and guidelines (NICE, ACP) report insufficient evidence or recommend against routine use

Heterogeneous protocols and small trials limit confidence

MENS evidence: MENS/MCT evidence is limited and inconsistent; small RCTs show modest benefit in select conditions but larger comparative trials are lacking

Insufficient large controlled trials

Guideline positions: Major guidelines conclude insufficient evidence to support IFT for LBP or OA and recommend conservative therapies first-line

NICE explicitly recommends against certain uses

Evidence-based coverage groupings

Coverage considerations based on current evidence and guidelines in this section:

Microcurrent therapies (MCT/MENS): Small RCTs and nonrandomized studies report short-term pain/function improvements in select conditions without serious adverse events, but heterogeneity and small sample sizes limit generalizability; further high-quality RCTs required

Percutaneous electrical nerve stimulation (PENS): Systematic reviews and RCTs show immediate to short-term pain reduction and some functional gains in MSK and postoperative settings, but long-term efficacy is unproven and guideline positions vary (NICE recommends against PENS for LBP)

PENFS and IB-Stim: Evidence base is weak and limited to small studies and registries; current assessments (Hayes) do not support routine coverage for many indications

Evidence summaries

Summary statements and evidence characterization from the document:

PENFS evidence summary: Auricular PENFS shows short-term analgesic effects in small RCTs and observational studies for some pediatric and postoperative indications, but evidence is limited and heterogenous

Further large RCTs needed

PNS evidence summary: Percutaneous PNS shows clinically meaningful pain reductions in selective trials (including responder rates up to ~87% in some studies), but overall evidence quality is low to moderate with heterogeneity and limited long-term, blinded RCT data

Safety profile generally favorable; common mild adverse events include lead migration and skin irritation

Consideration for implantable PNS

Evidence- and guideline-informed context for consideration of PNS/PNFS:

Guideline-based considerations: Implantable PNS may be considered in patients with moderate to severe chronic pain refractory to two or more conservative treatments; ASIPP supports implantable PNS after prior conservative treatment failurestwo or more conservative treatments

Temporary or trial PNS often used prior to permanent implant per guidelines

Evidence of clinical benefit (select trials)

Clinical outcomes reported in trials and series (context for medical necessity determinations):

Reported beneficial outcomes: Selected RCTs and case series report responder rates (≥50% pain reduction) ranging from ~60% to 87% in targeted populations, improvements in walking/function after TKA, and sustained pain reduction up to 12–14 months in some PNS series>=50% pain reduction

Study limitations include small size, heterogeneity, and potential funding biases

PNFS / SubQ — situations with positive RCT evidence

Evidence-supported situations (based on RCTs summarized):

PNFS/SubQ evidence: Subcutaneous PNFS added to SCS improved back pain outcomes in participants with FBSS who had adequate leg relief but residual back pain (higher proportion achieving ≥50% back pain reduction at 3 months in SubQ add-on group)

Evidence from multicenter RCTs and smaller RCTs with limitations

PEMF — evidence considerations

PEMF therapy — mixed/insufficient evidence summary:

PEMF overall conclusion: Systematic reviews and RCTs report variable short-term pain and function benefits in OA and nonspecific LBP, but heterogeneity in parameters, small samples, and short follow-up limit confidence; routine use is not well-supported

AAOS downgraded recommendation to 'limited' for wearable PEMF in knee OA

Restorative neurostimulation — not supported

Restorative neurostimulation:

Restorative neurostimulation conclusion: Published evidence is insufficient to support restorative neurostimulation for chronic low back pain as a routine therapy; additional larger comparative studies are needed

Policy identifies insufficient evidence and potential noncoverage absent stronger data

Restorative neurostimulation — trial-based eligibility

Evidence and trial-derived eligibility elements relevant to coverage decisions for restorative neurostimulation:

Restorative neurostimulation trial-derived eligibility: Pivotal trials enrolled patients with refractory mechanical CLBP associated with multifidus dysfunction, prior failure of >90 days of medical management, at least one attempt of physical therapy, and baseline ODI and NRS scores consistent with trial inclusion; trials randomized after implant or used strict selection criteria>90 days conservative care prior to implant

Payer may require similar documentation to align with trial populations

Evidence limitations

Evidence limitations that affect coverage stance:

Major evidence concerns: Concerns include small sample sizes, single-arm or single-center designs, high risk of bias, manufacturer funding and author conflicts of interest, lack of independent replication, and limited comparative data versus active treatments

ECRI and Hayes assessments highlight inconclusive evidence in multiple areas

Scrambler therapy — evidence summary

Scrambler therapy trial findings and implications for coverage:

Scrambler therapy evidence: RCTs and pilot studies show short-term pain reductions in some conditions (poststroke pain, CIPN, PDN) but are limited by small sizes, heterogeneous populations, short follow-up, and inconsistent long-term benefit; meta-analyses report marginal pain decreases at end of treatment and reduced analgesic use but recommend larger RCTs

Guidelines (ASCO, ESMO) do not support routine use outside trials for some indications

PEMF — guideline summary

PEMF guidance from professional society:

PEMF (wearable) recommendation: AAOS downgraded recommendation for wearable PEMF in knee OA to 'limited', citing feasibility and access concerns and calling for larger RCTs to identify responders

Evidence-based considerations for scrambler therapy

Summary of evidence-based coverage considerations

Evidence summary: Scrambler therapy evidence is mixed and generally low to very low quality: some small RCTs and systematic reviews report short-term pain reduction, but heterogeneity, small samples, and methodological limitations preclude strong coverage support; recommend use in clinical trial settings or with robust prior-authorization criteria

See systematic reviews and guideline statements

Evidence-based considerations for translingual stimulation

Summary of evidence-based coverage considerations for TLS/PoNS

Evidence summary: Translingual stimulation (PoNS) combined with targeted physical therapy has RCT data showing improvements in balance and gait in mmTBI and some pilot MS data, but trials are limited by small samples, variable dosing, and potential trial-center bias; additional larger sham-controlled trials are needed before routine coverage

Evidence often delivered as adjunct to supervised PT

Functional electrical stimulation (FES) is medically necessary only for the specific spinal cord injury (SCI) ambulation criteria listed in the policy. Covered prerequisites include intact lower motor units (L1 and below), adequate muscle/joint stability for weight bearing, brisk electrically evoked contraction, sufficient sensation to permit contraction, independent transfer ability, hand/finger function to manipulate controls, demonstration of independent standing tolerance for at least 3 minutes, and being ≥ 6 months post recovery from SCI or restorative surgery. FES use for any other indications is explicitly described as unproven and not medically necessary due to insufficient evidence of efficacy.

Home-based FES programs for SCI rehabilitation lack sufficient peer‑reviewed evidence and are not supported by clinical position statements per available reviews. Hayes’ evidence brief concluded there are few published, peer‑reviewed studies (including limited abstracts and single‑arm reports), and therefore no clear support exists to generalize routine coverage for home‑based FES outside of well‑controlled research or documented clinical programs.

Stroke trials cited in the policy commonly excluded individuals with severe cognitive or communication disorders, severe cardiopulmonary/renal/hepatic impairment, presence of cardiac pacemakers, foot drop from peripheral nerve injury, and those with noncontinuous treatment or missing follow‑up. These exclusion elements are frequently used in RCTs to ensure participant safety and interpretability of functional outcomes.

The MyndMove device evidence for post‑stroke improvement in pain, spasticity, or quality of life is judged inconclusive. ECRI and other assessments identified only very small, single‑center randomized trials and pre‑post studies at high risk of bias, and concluded that larger, multicenter RCTs are needed before efficacy can be established.

Existing NMES evidence in chronic neurological disorders is concentrated in cerebral palsy and a small number of other pediatric conditions; systematic reviews note that most studies are small, heterogeneous, and focused on CP. The policy therefore cautions that benefits demonstrated in CP cannot be reliably generalized across all chronic neurological disorders without additional high‑quality trials.

Interferential therapy (IFT) has insufficient evidence to support safety or efficacy for musculoskeletal pain, fracture healing, or nonsurgical soft tissue injuries. Multiple professional guideline statements (including ACP and NICE) and systematic reviews conclude that IFT should not be routinely offered because studies are small, heterogeneous, and do not show consistent clinical benefit.

Device systems that lack published clinical studies (for example, the neo‑GEN‑Series/NEO GeneSys 2k per Hayes’ review) are not supported by the evidence. The absence of peer‑reviewed clinical data for such named devices is cited as a basis for denying coverage or requiring substantial additional justification.

NICE explicitly recommends against offering percutaneous electrical nerve stimulation (PENS) for low back pain with or without sciatica due to insufficient and low‑quality evidence; this guideline‑level negative recommendation is referenced in the policy rationale for noncoverage of PENS in that indication.

The document excerpt does not provide a discrete list of medical exclusion conditions beyond study‑level exclusions, but it notes that many devices and indications lack sufficient evidence and therefore would not be supported as routine care. In practice, absence of regulatory‑grade evidence or guideline support is cited as a reason to withhold coverage for certain device/indication combinations.

Several indications are noted as lacking robust peer‑reviewed evidence or guideline support (examples include superior cluneal neuralgia and shoulder subluxation after stroke). The policy lists such indications as not supported for routine coverage absent new, high‑quality studies.

Pulsed electromagnetic field (PEMF) therapy and restorative neurostimulation are described as having mixed or insufficient evidence for routine use across many pain indications. Systematic reviews and HTAs cited in the policy conclude that additional robust, comparative trials are required before routine coverage can be recommended.

ECRI’s assessments for restorative neurostimulation emphasized that the evidence is inconclusive, with many studies at high risk of bias and limited replication. ECRI recommended additional independent studies; where evidence remains inconclusive, payers may exclude coverage or require stronger justification.

Clinical guidelines and systematic reviews do not recommend scrambler therapy for chemotherapy‑induced peripheral neuropathy (CIPN) or broadly for cancer‑related pain. ASCO’s guideline and ESMO/EONS/EANO statements cite low‑quality evidence and advise against routine use outside of clinical trials, and systematic reviews characterize the overall scrambler body of evidence as heterogeneous and low/very‑low quality.

No peripheral nerve field stimulation (PNFS) devices have specific FDA approvals for pain or muscle rehabilitation; studies have used implantable pulse generators cleared/approved for spinal cord stimulation in an off‑label manner. The policy notes implant considerations and the lack of device‑specific approvals for PNFS indications.

A reference list is provided in the policy excerpt. The references themselves summarize primary studies, systematic reviews, and HTAs that underpin the coverage determinations, but the references section does not independently state coverage rules.

The policy groups modalities identified as unproven—including IFT, MENS, PENS/PNT, PENFS, percutaneous PNS, PNFS, PEMF, restorative neurostimulation, scrambler therapy, and translingual stimulation—and treats these as not medically necessary for pain or rehabilitation because the evidence is insufficient to demonstrate clinical efficacy.

An 8‑week RCT that combined strength training with electrical stimulation found a negligible effect on very weak muscles, leading the authors to conclude limited applicability of combined electrical stimulation and strength training in that specific context. This trial result is cited as evidence tempering expectations of broad functional benefit from combined approaches in very weak muscle groups.

Hayes and other HTA reports judged the quality of evidence for FES in some stroke and chronic indications as low to very low. These assessments emphasize inconsistent functional and quality‑of‑life improvements versus alternatives (for example, ankle‑foot orthoses) and the need for larger, standardized RCTs to establish durable benefits.

The policy states that many uses of FES after stroke—particularly evidence for long‑term rehabilitative benefit beyond device use and comparisons versus AFOs—are not established, reflecting the low or very low certainty ratings and inconsistent trial outcomes reported in HTAs.

For masticatory spasticity in cerebral palsy, randomized trials and systematic review evidence were assessed as very low certainty; the available data do not support routine use of botulinum toxin or masticatory strengthening programs with or without NMES for this indication and clinical decisions should be individualized.

NMES should not be considered a replacement for comprehensive pulmonary rehabilitation. Systematic reviews in COPD found limited and generally low‑quality evidence: NMES applied alone produced some improvements in quadriceps force and submaximal exercise performance but did not consistently improve peak oxygen uptake or health‑related quality of life, and evidence quality was low to very low.

NICE and other guideline reviews do not support IFT for knee osteoarthritis or chronic primary pain and recommend against offering IFT for low back pain; the policy cites these guideline positions and the limited RCT evidence as rationale for not supporting routine use.

Hayes’ HTA judged PENS evidence for chronic low back pain as very low quality and insufficient to draw definitive conclusions. Combined with NICE guidance recommending against PENS for low back pain, the policy frames PENS as an unproven therapy for CLBP when used as monotherapy.

The policy notes insufficient evidence to support routine use of some percutaneous peripheral nerve stimulation devices and indications. Published studies are limited to small trials, case series, and short follow‑up, and heterogeneity in populations and outcomes prevents generalizable coverage recommendations without further high‑quality data.

Small sample sizes, inconsistent outcome measures, short durations, and study heterogeneity limit confidence in percutaneous PNS indications. These methodological limitations are a recurrent theme that constrain the strength of coverage conclusions for PNS and related modalities.

Restorative neurostimulation (for example, multifidus stimulation/ReActiv8) is characterized by limited and inconclusive published evidence. Systematic assessments found RCTs and before‑after studies at high risk of bias and insufficient independent replication; the policy therefore treats restorative neurostimulation as lacking adequate evidence to support routine coverage.

Scrambler therapy evidence across indications is judged insufficient and of low to very‑low quality. Systematic reviews and HTAs indicate small, heterogeneous trials with short follow‑up and methodological limitations, leading to the conclusion that scrambler therapy is not supported for routine clinical use outside well‑controlled research settings.

Hayes’ systematic reviews consistently rated the scrambler therapy evidence base for both cancer‑related and noncancer chronic pain as low or very low quality, citing small sample sizes, lack of blinding, and limited follow‑up; Hayes recommends larger, well‑designed trials before efficacy can be concluded.

Coding and Product Codes

Referenced CPT Category IIICPT

0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment

Surgical neurostimulator CPT codesCPT

63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64567	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure).
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.

1–10 of 11

1/2

HCPCS / supplies / device codesHCPCS

A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556	Electrodes (e.g., apnea monitor), per pair.
A4557	Lead wires (e.g., apnea monitor), per pair.
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595	Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
E0720	Transcutaneous electrical nerve stimulation (TENS) device, two-lead, localized stimulation.
E0721	Transcutaneous electrical nerve stimulator, stimulates nerves in the auricular region.

1–10 of 28

1/3

E0770 PDAC-verified devicesmixed

E0770 - device examples

Devices validated by CMS PDAC to report with HCPCS E0770: Deluxe Digital Electronic Muscle Stimulator (Drive Medical); NESS L300 and H200 (Bioness); Odstock ODFS Pace FES System; WalkAide (Innovative Neurotronics).

No explicit CPT/HCPCS codes in this excerptmixed

No codes listed

PNFS / SubQ studies — no billing codes listed in this sectionmixed

No codes listed

PEMF studies — no billing codes listed in this sectionmixed

No codes listed

Restorative neurostimulation — no billing codes listed in this sectionmixed

No codes listed

Functional Electrical Stimulation device product codesmixed

GZI	FDA product code referenced for functional electrical stimulation devices

Neuromuscular electrical stimulation device product codesmixed

IPF	FDA product code referenced for neuromuscular electrical stimulation devices

Interferential therapy device product codesmixed

LIH	FDA product code referenced for interferential therapy devices

Pulsed electromagnetic field device product codesmixed

ILX	FDA product code referenced for pulsed electromagnetic field stimulation devices

Percutaneous/peripheral nerve stimulation device product codesmixed

NHI	FDA product code referenced for percutaneous/peripheral nerve stimulation devices
GZB	FDA product code referenced for percutaneous/peripheral nerve stimulation devices
GZF	FDA product code referenced for percutaneous/peripheral nerve stimulation devices

Peripheral nerve field stimulation device product codesmixed

LGW	FDA product code referenced for peripheral subcutaneous field stimulation devices (no specific device approvals for pain)

TENS / microcurrent / scrambler device product codesmixed

GZJ	FDA product code referenced for TENS/microcurrent devices and scrambler therapy device
NUH	FDA product code referenced for TENS devices
NGX	FDA product code referenced for TENS devices

Percutaneous electrical nerve field stimulation device product codesmixed

QHH	FDA product code referenced for IB-Stim percutaneous electrical nerve field stimulation (De Novo)
PZR	Alternate product code referenced for IB-Stim De Novo

Percutaneous electrical nerve stimulation device product codes (additional)mixed

BWK	FDA product code referenced for percutaneous electrical nerve stimulation devices

Restorative neurostimulation device product codesmixed

QLK	FDA product code referenced for ReActiv8 Implantable Neurostimulation System (PMA)

inv-70: Post recovery from SCI and restorative surgery — >= 6 months

Post-recovery timing>= 6 months after spinal cord injury or restorative surgery

Required functional prerequisiteDemonstration of independent standing tolerance for at least 3 minutes

Neuromuscular integrityIntact lower motor units (L1 and below) — muscle and peripheral nerves

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Recommended for Implantable Neuromodulation

Implantable neuromodulation (PNS/PNFS, restorative neurostimulation, implanted stimulators): prior authorization is recommended. Requests for implantable systems should include comprehensive clinical justification and documentation of prior conservative management failures.

Document trial stimulation results or temporary PNS/percutaneous trial when applicable.
Include device model, FDA product code or PMA reference (e.g., ReActiv8 QLK) and rationale for device selection.
Provide prior conservative therapy history (e.g., ≥90 days medical management and at least one attempt at PT when relevant).

Documentation Required

Prior Authorization — Clinical Data Required

Clinical data to support prior authorization should be supplied with the medical record. Incomplete documentation may lead to denial.

Conservative Care and Rehabilitation Requirements

Frequency and Treatment Regimens

inv-187: No explicit frequency limits stated in this portion of the document

Frequency limits summaryNo explicit frequency limits stated in this portion of the document

Coding section noteApplicable codes and supply codes are listed but do not define treatment frequency

Provider action implicationFrequency should follow evidence protocols or device labeling since policy does not specify limits

inv-188: Implantation of peripheral nerve stimulation or peripheral nerve field stimulation devices — procedural frequency context

Procedure contextImplantation involves placing electrode(s) near peripheral nerves (PNS) or subcutaneous field arrays (PNFS)

Implantable systems referencedExamples include StimRouter, SPRINT, ReActiv8 (implantable PNS and restorative neurostimulation systems)

Imaging and Procedural Guidance Considerations

Note

Definitions and Background on Electrical Stimulation Modalities

Electrical stimulation modalities deliver currents to nerves or muscles to reduce pain, produce muscle contraction, and support rehabilitation. The policy distinguishes modalities by therapeutic intent (e.g., FES to produce functional movements versus NMES for muscle re‑education and prevention of atrophy) and uses evidence synthesis to determine which indications are proven, covered, unproven, or not medically necessary.

inv-135: FES — Functional electrical stimulation definition

DefinitionFunctional Electrical Stimulation (FES): direct application of electric current to intact nerve fibers to produce involuntary but purposeful muscle contractions to enable or enhance functional movements

TargetsTargets motor neurons to produce movements such as standing, ambulation, grasping, respiration, and bowel/bladder function

Delivery modesElectrodes may be surface-mounted or surgically implanted; used therapeutically and functionally

inv-136: NMES — Neuromuscular electrical stimulation definition

Not Covered / Excluded Modalities

The policy lists multiple modalities as not covered or unproven, specifically naming interferential therapy (IFT); microcurrent electrical nerve stimulation (MENS); and percutaneous electrical nerve stimulation (PENS/PNT) among others. These modalities are considered experimental or not medically necessary because current peer‑reviewed evidence does not demonstrate consistent clinical benefit.

Policy Revision History

2026-05-01Policy updateLatest

Effective 2026-05-01: Revised coverage rationale and updated list of unproven/not medically necessary indications; added documentation language and CPT/HCPCS code updates (added CPT 64567; removed CPT 0720T); updated supporting sections and archived prior policy version CS036PA.V.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Pennsylvania Only)

Policy CodePolicy CS036PA.W

Change TypeNo material changes

Effective DateMay 1, 2026

Next Review Date

SourceLink

On This Page

Populations with unclear evidence: Home-based FES for SCI rehabilitation and pediatric incomplete SCI populations have insufficient or unclear evidence to support routine coverage

Hayes and other assessments note insufficient evidence for these contexts

NMES added to conventional rehabilitation after joint replacement or ACL reconstruction often improves quadriceps strength and some functional measures; protocols and long-term impact vary across studies

Early NMES (≤1 week) may show larger short-term effects

Poststroke motor recovery: Contralaterally controlled FES (CCFES) may improve some upper-extremity measures versus cyclic NMES in certain trials, but evidence is heterogeneous and not uniformly superior

Additional well-designed trials needed

Ability to transfer independently and hand/finger function to manipulate controls

Contraindications absentNo hip/knee degenerative disease and no history of long-bone fracture secondary to osteoporosis

inv-71: Independent standing tolerance for FES candidacy — >= 3 minutes

Standing tolerance threshold>= 3 minutes of independent standing tolerance required for FES candidacy

Functional requirement contextUsed to demonstrate ability to maintain upright support posture independently

Associated criteriaRequires muscle and joint stability for weight-bearing and brisk muscle contraction

Device-control requirementDemonstration of hand and finger function to manipulate device controls

inv-72: Study follow-up durations — 2 to 240 weeks

Range of follow-up durations in trials2 to 240 weeks (reported across included knee OA and rehabilitation trials)

Typical short-term follow-upMany RCTs report outcomes at 2–12 weeks

Longer follow-up examplesSome studies and registries include follow-up to 12 months or longer

History and physical exam supporting diagnosis and symptom severity.
Relevant diagnostic tests (e.g., MRI/CT, imaging or physiological testing documenting multifidus dysfunction for ReActiv8).
Baseline pain scores, functional status (ODI, VAS/NRS), and prior conservative treatment details and duration.
Trial outcomes (pain reduction %, functional change) with objective measures where available.

Prior Authorization

Device‑Specific Justification Recommended

For device-specific or proprietary therapies (e.g., MyndMove, WalkAide, Odstock, StimRouter, SPRINT, ReActiv8, Nalu), include a device-specific justification and supporting evidence in the request.

Identify the device and provide FDA product code or PMA reference when available.
Summarize key supporting literature (trial design, outcomes, duration) and how the member matches study eligibility.
Explain why the chosen device is indicated over alternative therapies or devices.

Note

Prior Authorization Not Specified in Policy Excerpt — Check Benefits

Some services and devices in this policy do not have explicit prior authorization rules in this excerpt. Refer to benefit plan and local payer rules to determine authorization requirements.

Applicable billing codes listed are for reference only and do not imply coverage or authorization status.
Check the member's contract and state-specific requirements (Pennsylvania Code Title 55, Chapter 1101.31) for plan-specific authorization rules.

Prior Authorization

Prior Authorization for Limited‑Evidence Modalities May Be Required

Modalities with limited or low-quality evidence (e.g., IFT for many MSK indications, PEMF, some PNS indications, home-based FES, novel proprietary systems lacking peer-reviewed studies) may trigger prior authorization, additional documentation requests, or denial.

When evidence is limited, submit documentation of prior therapies attempted, objective baseline measures, and rationale for choosing the modality.
Include peer-reviewed literature or HTA assessments when available (e.g., Hayes, ECRI).

Documentation Required

Provider Training and Credential Documentation

Procedures that require specialized practitioner skills (e.g., PENS) should document provider training and credentials. Lack of training documentation may affect approval.

Include practitioner training, credentialing, and details of the technique (e.g., ultrasound guidance, needle parameters).
If the therapy requires specific device training or manufacturer certification, include evidence of completion.

Prior Authorization

Prior Authorization Recommended for Implantable PNS

Requests for implantable PNS should document prior conservative treatment failures and reference guideline context when available. Prior authorization is recommended for implantable PNS.

State prior treatments tried (medications, PT, injections) and duration.
Provide trial stimulation results if performed (degree and duration of pain reduction).
Reference guideline recommendations (e.g., ASIPP) when supporting implantable PNS requests.

Prior Authorization

Prior Authorization Requirements — What to Submit

When prior authorization is required, submit trial stimulation results, indication-specific documentation, and supporting literature. Absent or inadequate information may result in denial.

Trial stimulation documentation: stimulation parameters, duration, responder rates (e.g., ≥50% pain reduction).
Indication-specific details: diagnosis confirmation, symptom duration, functional impact.
Relevant literature or HTA summaries supporting clinical decision-making.

Prior Authorization

Prior Authorization — Restorative Neurostimulation

Restorative neurostimulation (e.g., ReActiv8) prior authorization should include documentation of failed conservative therapies, baseline measures, and trial or device-specific study alignment. Evidence is currently insufficient to conclusively demonstrate efficacy; careful documentation is needed.

Document >90 days of medical management and at least one PT attempt when applicable.
Provide baseline ODI, VAS/NRS, and imaging/physiological evidence of multifidus dysfunction.
Include applicable clinical trial data and long-term outcomes if available.

Denial Risk

Documentation‑Related Denial Risk

Lack of adequate documentation supporting medical necessity is a common reason for denial. Ensure medical records fully support the requested service.

Provide legible, retrievable medical records with history, exam, diagnostic results, and prior treatment timelines.
Failure to supply complete records upon request may result in denial.

Denial Risk

Home‑Based FES — Evidence Limitations and Coverage Risk

Home‑based FES evidence is limited. Clinical position statements and robust peer‑reviewed literature are lacking; coverage is uncertain and may be denied without strong supporting documentation.

If requesting home-based FES, submit evidence of medical necessity, supervised training plan, and rationale for home use vs in‑clinic therapy.
Include HTA evidence (e.g., Hayes) or other high-quality studies if available.

Denial Risk

Evidence‑Related Denial Risk

Across modalities, inconsistent, low-quality, or very low-quality evidence may lead to denial or requirement for additional documentation. Be prepared to justify anticipated clinical benefit.

Identify study quality and applicability to the patient (population, duration, outcomes).
When evidence is low-quality, describe individualized rationale and prior standard therapies exhausted.

Denial Risk

Evidence Quality May Affect Coverage

In some indications evidence quality directly affects coverage decisions. Provide high-quality supporting literature when possible; absence of such evidence may result in noncoverage.

Cite systematic reviews, RCTs, HTAs (Hayes, ECRI) to support requests.
Highlight where the member matches trial eligibility to strengthen applicability.

Note

Not Applicable — No Additional Authorization Rules in Excerpt

Not applicable in this excerpt: no explicit additional plan-level prior authorization rules are stated beyond the guidance above. Verify plan-specific PA pathways.

Use the payer's prior authorization portal or provider services to confirm operational requirements.

Denial Risk

IFT Evidence Insufficiency — Coverage Considerations

Interferential Therapy (IFT): evidence is insufficient to support many MSK indications; prior authorization or denial is possible depending on indication and documentation.

When requesting IFT, submit indication-specific evidence and prior conservative therapy attempts.
Reference professional guidance (ACP, NICE) where relevant.

Denial Risk

Devices Lacking Clinical Evidence — Expect Additional Scrutiny

Devices or treatments lacking peer‑reviewed clinical evidence (e.g., neo‑GEN-Series, certain proprietary systems) will likely require additional justification and may be denied.

Provide any available clinical study data, HTA summaries, or rationale for experimental/off‑label use.
If no evidence exists, consider clinical trial enrollment or alternative covered therapies.

Denial Risk

Evidence Insufficiency Risk — May Lead to Denial

Insufficient or low‑quality evidence across several modalities (PNS, PNFS, PEMF, restorative neurostimulation, scrambler therapy) may trigger denials; submit robust documentation to mitigate risk.

Include objective baseline and follow‑up outcome measures, trial stimulation data, and prior treatment history.
When evidence is heterogeneous, explain why the member is a reasonable candidate despite limitations.

Documentation Required

Trial-Based Clinical Eligibility Details — Include in Request

When evidence is insufficient, specify applicable study eligibility (trial‑based clinical criteria) and how the member meets those criteria to support the request.

Describe trial inclusion/exclusion parallels (e.g., time since event, muscle strength grades, ability criteria).
Provide imaging/diagnostic confirmation used in relevant trials (CT/MRI, neurophysiology).

Documentation Required